SCHEMBL115429

SCHEMBL115429

O=S(=O)(O)N1C=CCc2ccccc21

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
MITF O75030 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
ALDH1A1 P00352 3/20 0.33
POLB P06746 2/20 0.33
HSD17B10 Q99714 2/20 0.32
NOTUM Q6P988 2/20 0.32
MYC P01106 1/20 0.32
TSHR P16473 3/20 0.31
LMNA P02545 1/20 0.31
THRB P10828 1/20 0.31
PMP22 Q01453 1/20 0.31
MAPT P10636 1/20 0.31
HSD17B3 P37058 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL461238 0.82 CA2 (0.35) NPC1RAB9AMITFMEN1KMT2A
SCHEMBL553792 0.71 NPC1 (0.35) NPC1RAB9AMITFMEN1KMT2A
SCHEMBL1375450 0.71 NPC1 (0.35) NPC1RAB9AMITFMEN1KMT2A
SCHEMBL3267875 0.70 MAPT (0.35) NPC1RAB9AMITFMEN1KMT2A
SCHEMBL10841005 0.69 NPC1 (0.39) NPC1RAB9AMITFMEN1KMT2A
SCHEMBL1629578 0.69 NPC1 (0.39) NPC1RAB9AMITFMEN1KMT2A
SCHEMBL374979 0.69 ALDH1A1 (0.33) NPC1RAB9AMITFMEN1KMT2A
SCHEMBL3266678 0.68 MEN1 (0.41) NPC1RAB9AMITFMEN1KMT2A
SCHEMBL15010759 0.67 POLB (0.33) NPC1RAB9AMITFMEN1KMT2A
SCHEMBL4838387 0.67 HTR2A (0.36) NPC1RAB9AMITFMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210292347-A1 DIHETEROCYCLIC TRIAZINONE NUCLEOSIDE ANALOGS AND THEIR USE FOR MEDICATION XU LIFENG (US) 2021-09-23 US claimed
EP-1599555-B1 CMP COMPOSITION COMPRISING A SULFONIC ACID AND A METHOD FOR POLISHING NOBLE METALS CABOT MICROELECTRONICS CORP (US) 2019-06-12 EP claimed
EP-3125857-A1 COMPOSITIONS AND METHODS FOR ENHANCING THE TOPICAL APPLICATION OF A BASIC BENEFIT AGENT Johnson & Johnson Consumer Inc. (US) 2017-02-08 EP claimed
US-9474699-B2 Compostions and methods for enhancing the topical application of a basic benefit agent JOHNSON & JOHNSON CONSUMER INC. (US) 2016-10-25 US claimed
WO-2015153074-A1 COMPOSITIONS AND METHODS FOR ENHANCING THE TOPICAL APPLICATION OF A BASIC BENEFIT AGENT JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2015-10-08 WO claimed
US-20150272834-A1 COMPOSTIONS AND METHODS FOR ENHANCING THE TOPICAL APPLICATION OF A BASIC BENEFIT AGENT JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2015-10-01 US claimed
US-20150150893-A1 ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION LIAONING LIFENG SCIENT & TECHNOLOGY DEV COMPANY LTD (CN) 2015-06-04 US claimed
JP-4709136-B2 2011-06-22 JP claimed
WO-2007145991-A2 ANTI-INFLAMMATORY AND ANALGESIC COMPOSITIONS AND RELATED METHODS LIPOCINE, INC. (US) 2007-12-21 WO claimed
US-20070281927-A1 Anti-inflammatory and analgesic compositions and related methods LIPOCINE, INC. 2007-12-06 US claimed
US-20050181041-A1 Method of preparation of mixed phase co-crystals with active agents MEDCRYSTALFORMS, LLC (US) 2005-08-18 US claimed
WO-2005055983-A2 METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS MEDCRYSTALFORMS, LLC (US) 2005-06-23 WO claimed
WO-2004076574-A2 CMP COMPOSITION COMPRISING A SULFONIC ACID AND A METHOD FOR POLISHING NOBLE METALS CABOT MICROELECTRONICS CORPORATION (US) 2004-09-10 WO claimed
US-20030181142-A1 CMP method for noble metals CABOT MICROELECTRONICS CORPORATION 2003-09-25 US claimed
EP-1210063-A1 COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS Lipocine, Inc. (US) 2002-06-05 EP claimed
US-6383471-B1 DRUG DELIVERY LIPOCINE, INC. 2002-05-07 US claimed
EP-1165048-A1 COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS Lipocine, Inc. (US) 2002-01-02 EP claimed
US-6309663-B1 Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents LIPOCINE INC. 2001-10-30 US claimed
WO-2001012155-A1 COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS LIPOCINE, INC. (US) 2001-02-22 WO claimed
WO-2000059475-A1 COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS LIPOCINE, INC. (US) 2000-10-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292347-A1 DIHETEROCYCLIC TRIAZINONE NUCLEOSIDE ANALOGS AND THEIR USE FOR MEDICATION NTPCR, ENTPD5, DPYD NPC1 132/4885RAB9A 2561/4885MITF 1549/4885
US-20150150893-A1 ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION CYP11B1, CYP51A1, CYP11B2 NPC1 115/4885RAB9A 427/4885MITF 1344/4885
US-20070281927-A1 Anti-inflammatory and analgesic compositions and related methods MB, PTGS1, PTGS2 NPC1 3650/4885RAB9A 4273/4885MITF 1002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.